Teva Pounces On US Revlimid Opportunity With Four Strength-Offering
Israeli Firm Has Partnered With Natco; December 2015 Settlement Provides For Entry
Executive Summary
Teva has bolstered its oncology offering in the US by moving first on one of the largest small-molecule opportunities in the US: Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) to treat multiple myeloma.
You may also be interested in...
Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics
With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.
Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics
With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks to Generics Bulletin about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.
Reddy’s Exclusivity End Allows Teva, Natco To Match Full US Revlimid Suite
Teva has moved fast to match Dr Reddy’s Laboratories’ complete six-strength offering of generic Revlimid (lenalidomide) products in the US.